Assessment of Erythropoiesis-Stimulating Agents for Anemia Treatment among Chronic Kidney Disease Patients: A Descriptive, Retrospective Study
Background: Renal anemia is a cause of significant morbidity, and to lesser extent mortality in patients with chronic kidney disease (CKD), the leading causes of anemia in CKD primarily are the lack of erythropoietin (EPO) and iron. Thus, effective management is possible using oral and intravenous (...
Main Authors: | Zeinab Mohamed Elamin, Safaa Badi, Bashir Alsiddig Yousef |
---|---|
Format: | Article |
Language: | English |
Published: |
Zibeline International
2021-01-01
|
Series: | Matrix Science Medica |
Subjects: | |
Online Access: | http://www.matrixscimed.org/article.asp?issn=2521-0807;year=2021;volume=5;issue=1;spage=21;epage=24;aulast=Elamin |
Similar Items
-
Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?
by: Szu-Chun Hung, et al.
Published: (2014-01-01) -
Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
by: Timothy V. Nguyen, et al.
Published: (2011-11-01) -
Anemia of Inflammation with An Emphasis on Chronic Kidney Disease
by: Sajidah Begum, et al.
Published: (2019-10-01) -
Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
by: Bergur V. Stefánsson, et al.
Published: (2011-08-01) -
Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents
by: N. A. Romanenko, et al.
Published: (2014-07-01)